BS
Founder and CEO of CpG Diagnostics.
View personal profileCD
CpG Diagnostics is developing a blood test to help clinicians assess ovarian-area masses before treatment.
Overview
CpG Diagnostics is developing OvaPrint for clinicians assessing whether an ovarian-area mass is benign or malignant. The proposed blood test analyzes DNA methylation patterns and is undergoing clinical validation.
The company plans initial self-pay access without established insurance coverage. OvaPrint is not yet commercially available.
- Operated by
- CpG Diagnostics, Inc.
Loading profile details…
Industries
- Industry category
- Healthcare & Life Sciences
- Specific industry
- Biotech Research
Classification sources and history
Biotech Research · Business involvement
As of 2026-11-08
Loading recent changes…
Sources & editorial review
(3)
Editorial profile by MoneyMakers. Sources reviewed .
